Open AccessCost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor
Author(s) -
Roberto Ravasio,
Holly Cranmer,
Izzie Kearns,
Raffaella Viti,
Simone Corinti
Publication year - 2022
Publication title -
aboutopen
Language(s) - English
Resource type - Journals
ISSN - 2465-2628
DOI - 10.33393/ao.2022.2450
Subject(s) - alectinib , medicine , anaplastic lymphoma kinase , clinical trial , oncology , alk inhibitor , lung cancer , adverse effect , malignant pleural effusion